The Evidence MultiSTAT - Advancing Workplace Drug Testing

26 September 2017
The Evidence MultiSTAT - Advancing Workplace Drug Testing

Growth of drug abuse in the workplace has been an increasing challenge in America. An estimated two-thirds of opioid users reported pain relief misuse whilst on the payroll. Drug misuse in the workplace poses a danger to the employee and their colleagues, affecting the productivity of the business.

Randox Toxicology highlight the importance of workplace drug testing, with the use of the Evidence MultiSTAT. Using our revolutionary Biochip Array Technology, our automated analyser enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs from a single sample. Our versatile analyser uses a simple process which can be carried by non-laboratory staff, providing highly accurate qualitative results.

The Evidence MultiSTAT
The Evidence MultiSTAT cuts costs for businesses using third-party clinics to conduct drug tests. According to a recent Chicago Tribune article, Tulkoff’s food-processing plant in Baltimore practices a zero-tolerance policy, but feel that time and money is wasted training employees who fail the screening process and therefore quit.

According to the American National Safety Council, 57 percent of businesses perform workplace drug testing. Over 40 percent of which do not screen for synthetic opioids such as fentanyl and oxycodone. The  Evidence MultiSTAT’s extensive test menu can detect fentanyl and oxycodone, among other dangerous drugs on oral fluid, whole blood, and urine.

If you would like to find out more about our revolutionary product range and DoA test menus, email us at info@randoxtoxicology.com

UK: +44 (0)28 9442 2413
USA: +1 304 728 2890